Bridging the Survival Gap: The Fight Against Childhood Cancer
By Staff Writer
February 15, 2024
Introduction:
On International Childhood Cancer Day 2024, we take this opportunity to highlight the significant contribution that parents, family physicians, and paediatricians make to the early detection of cancers in children. On a daily basis, childhood cancer affects some of the most vulnerable communities. Globally the focus is shifting more and more towards the importance of early detection. The survival rates of children with cancer vary dramatically between high-income and low- to middle-income countries.
The Global Childhood Cancer Burden
Every day, over 1000 children worldwide are diagnosed with cancer. In high-income countries, advancements in medical technology have led to survival rates exceeding 80%. However, in some low- and middle-income countries, only about 20% of children diagnosed with cancer survive. Not only does the enhancement of cancer care for children present a significant opportunity to save lives and alleviate suffering, but it also has the potential to accelerate the development of a cancer control program that is more inclusive and to demonstrate success in the larger child health and noncommunicable disease (NCD) agenda.
The WHO’s Global Initiative for Childhood Cancer Survival Gap
In 2018, the World Health Organisation (WHO) together with St. Jude Children’s Research Hospital and other global partners launched the Global Initiative for Childhood Cancer (GICC). This initiative aims to bridge the childhood cancer survival gap by 2030. Ensuring at least 60% of children with cancer worldwide survive their diagnosis. Through the utilisation of the CureAll framework as the coordinated operational strategy, the Initiative functions to bring together stakeholders from a variety of sectors in order to achieve a common objective.
The Role and Impact of Parents
Parents play a critical role in early detection of childhood cancer. Early detection requires identification of signs and symptoms in young children who may not be able to express them. Parents must be aware of these signals to ensure timely diagnosis and staging. Knowing the early signs and symptoms of specific cancers and being vigilant could potentially save a child’s life.
Figure 1: Percentage of countries with early detection programmes/guidelines and referral system for suspected childhood cancer cases, by World Bank income group, 2019
The Fight Against Childhood Cancers
Many low- and middle-income countries still struggle with early diagnosis and treatment of childhood cancer. Recent data shows that only 20% of nations globally report having early detection programs or guidelines to enhance early diagnosis of childhood cancer symptoms at primary care level (Figure 1). There is a clear need for a more accessible and well-defined referral system for suspected childhood cancer cases. This system should span from primary care to intermediate and tertiary care. This system, unfortunately, is only in place in one third of the globe.
Conclusion:
International Childhood Cancer Day is an opportunity for us all to contribute to a future where every child, irrespective of their birthplace, has the chance to live a healthy life. It’s not just about raising awareness; it’s a call to action for everyone to join the fight against childhood cancer. There is no way to understate the importance of raising awareness and educating people, particularly parents, about childhood cancer.
💡 Can the U.S. lower drug prices by 30–80% while improving access and preserving innovation?
President Trump’s recent Executive Order lays the groundwork for bold reforms—targeting international price gaps, PBM markups, and regulatory delays.
This article applies a systems dynamics approach to identify leverage points and feedback loops driving high U.S. drug costs—and outlines concrete, policy-based strategies to reverse them.
Explore how systemic thinking can drive sustainable, scalable change in U.S. pharmaceutical pricing.
💡 How can the EU strengthen its pharmaceutical sector for the future?
The EFPIA has laid out critical recommendations for the next EU Multiannual Financial Framework (2028-2034), focusing on boosting funding for life sciences research, enhancing regulatory competitiveness, and improving health data infrastructure. These insights could significantly shape the future landscape of healthcare in Europe.
Dive into the full article to learn how these recommendations aim to propel innovation and increase access to medicines across Europe!
🌟 Are you ready to embrace a new era in health technology evaluations?
Our latest article dives into the recent updates from NICE regarding the incorporation of patient perspectives and tackling health inequalities in their health technology assessments. By exploring stakeholder feedback and proposed methodologies, we uncover a shift towards more inclusive and transparent evaluations that could reshape market access and reimbursement policies in the UK healthcare system.
Don’t miss out on these vital insights that could impact your understanding of healthcare value! Read the full article [here](https://www.nice.org.uk/process/pmg36/documents/consultation-comments-and-responses).
#SyenzaNews #HealthEconomics #MarketAccess
When you partner with Syenza, it’s like a Nuclear Fusion.
Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in
health policy, health economics, systems analysis, public finance, business, and project management.
You’ll also feel our high-impact global and local perspectives with cultural intelligence.